新型抗过敏药物3'-（1H-四氮唑-5-基）氧苯甲酸丁酯的免疫药理作用。第三次通讯：对肺组织碎片组胺释放、离体气管平滑肌舒尔茨-戴尔反应及豚鼠实验性哮喘的抑制作用
Immunopharmacological actions of the new antiallergic drug butyl 3'-(1H-tetrazol-5-yl)oxanilate. 3rd communication: inhibitory effects on histamine release from lung fragments, Schultz-Dale reaction in isolated tracheal muscle and experimental asthma in guinea pigs.
作者信息
Yanagihara Y, Abe T, Kuroda T, Shida T
机构信息
Clinical Research Center for Allergy, National Sagamihara Hospital, Kanagawa, Japan.
出版信息
Arzneimittelforschung. 1988 Jan;38(1):80-3.
The inhibitory effects of butyl 3'-(1H-tetrazol-5-yl) oxanilate (WP-833), a new antiallergic drug, on histamine release from lung fragments, Schultz-Dale (SD) reaction in isolated tracheal muscle and experimental asthma were investigated in guinea pigs passively sensitized with homologous immunoglobulin E (IgE) serum. WP-833 dose-dependently inhibited antigen-induced histamine release from lung fragments. In addition, synergism as to inhibition of histamine release was observed with a combination of WP-833 and isoprenaline but not with that of WP-833 and theophylline. WP-833 also inhibited antigen-mediated SD reaction of isolated tracheal muscle without showing antagonistic actions upon histamine- and leukotriene D4-induced contraction of normal tracheal muscle. Experimental asthma was clearly inhibited in a dose-dependent fashion by oral administration of WP-833.
新型抗过敏药物3'-（1H-四氮唑-5-基）氧苯甲酸丁酯（WP-833）对豚鼠经同源免疫球蛋白E（IgE）血清被动致敏后肺组织碎片中组胺释放、离体气管肌肉舒尔茨-戴尔（SD）反应及实验性哮喘的抑制作用进行了研究。WP-833呈剂量依赖性抑制抗原诱导的肺组织碎片组胺释放。此外，观察到WP-833与异丙肾上腺素联合使用对组胺释放的抑制有协同作用，但与WP-833和茶碱联合使用时未观察到协同作用。WP-833还抑制离体气管肌肉的抗原介导SD反应，对组胺和白三烯D4诱导的正常气管肌肉收缩未表现出拮抗作用。口服WP-833能明显呈剂量依赖性抑制实验性哮喘。
Zotero 插件